Señuelo dirigido a HIF-1 potencializa efectos citotóxicos de dos agentes quimioterapéuticos en MDA-MB-231
HIF decoy improve cytotoxic effects of two chemotherapeutic agents on MDA-MB-231
A decoy dirigida ao HIF-1 potencializa os efeitos citotóxicos de dois agentes quimioterápicos em MDA-MB-231
DOI:
https://doi.org/10.15446/rev.colomb.biote.v22n2.73114Keywords:
Cáncer, hipoxia, proliferación celular, apoptosis, sinergia (es)Downloads
Procesos oncogénicos como proliferación incontrolable, resistencia apoptótica, aumento de mecanismos angiogénicos y evasión inmune son regulados generalmente por factores de transcripción, como HIF-1. Por tanto, se ha señalado a esta molécula como un blanco terapéutico prometedor. Para explorar esta posibilidad, un oligonucleótido tipo “señuelo” dirigido a HIF-1α (ODN) fue diseñado para evaluar su eficiencia en esquema tanto monoterapéutico, como en combinación con dos agentes quimioterapéuticos en un modelo in vitro de cáncer de seno. Después de comprobar, mediante citometría de flujo e inmunofluorescencia, la localización del blanco, el señuelo fue transfectado en la línea celular MDA-MB-231. Se estableció la IC-50 de HIF-1α ODN, Cisplatino y Taxol con el método de Resazurina. Mecanismos de muerte celular fueron evaluados con el método de TUNEL. Por último, se estableció el índice de combinación (IC) de cada uno de los quimio-agentes en combinación con el ODN. Se evidencio que HIF-1α ODN causa un efecto citotóxico en MDA-MB-231 de hasta un 90% hacia las 72h pos-tratamiento. Este efecto no se observa tanto en los controles del ensayo, como en el cultivo primario de células no tumorales (FIBRO), siendo este agente altamente selectivo hacia células tumorales, al activar mecanismos pro-apoptóticos. A su vez, HIF-1α ODN potencializa la actividad tumorogénica de Cisplatino y Taxol en la línea celular tumoral. Por tanto, HIF-1α ODN demostró tener actividad selectiva potencialmente antitumoral, al disminuir la proliferación celular e inducir apoptosis; optimizando de forma sinérgica, la eficacia de fármacos quimioterapéuticos de alto espectro, en tratamientos combinados.
Oncogenic processes like uncontrollable proliferation, resistance to apoptosis, increases in angiogenic mechanisms and immune evasion are regulated by transcription factors such HIF-1. Therefore, this molecule is regarded as a potential therapeutic target. To explore this possibility, a HIF-1α oligonucleotide decoy (ODN) was designed to evaluate its efficiency on both a mono-therapeutic scheme and a mixed treatment with two chemotherapeutic agents within an in vitro model of breast cancer. After confirming the target location with flow cytometry and immunofluorescence assays, that decoy was transfected over the MDA-MB-231 cell line. We established the HIF-1α ODN, Cisplatin and Taxol IC-50 using Resazurin tests. Cell death mechanisms was evaluated with TUNEL. Finally, we obtained the combination index (IC) of each chemical agents with the ODN. This study showed that HIF-1α ODN caused a cytotoxic effect (up to 90%) in MDA-MB-231 during 72 hours post treatment. That effect did not appear in either the assay controls nor in non-tumor cell cultures (FIBRO). This agent is highly selective towards tumor cells, activating pro-apoptotic mechanisms. Additionally, HIF-1α ODN increases the tumorigenic action of Cisplatin and Taxol on the cell line, due to an additive effect. For these reasons, HIF-1α ODN has potential antitumor selective activity, decreasing cell proliferation, inducing apoptosis, and optimizing, in a synergistic manner, the efficacy of wide spectrum chemotherapeutic compounds when it used in a combined treatment.
Processos oncogênicos, como proliferação incontrolável, resistência à apoptose, aumento de mecanismos angiogênicos e evasão imune, são geralmente regulados por fatores de transcrição, como o HIF-1. Portanto, esta molécula tem sido indicada como um alvo terapêutico promissor. Para explorar esta possibilidade, um tipo de oligonucleido "decoy" direccionamento HIF-1α (ODN) foi desenhado para avaliar a sua eficiência como esquema de monoterapêutica ou em combinação com dois agentes quimioterapêuticos, em um modelo in vitro de cancer da mama. Após verificação, por meio de citometria de fluxo e imunofluorescência, a localização do alvo, o chamariz foi transfectado na linhagem celular MDA-MB-231. IC-50 de ODN, Cisplatina e Taxol de HIF-l α foi estabelecido com o método Resazurina. Os mecanismos de morte celular foram avaliados pelo método TUNEL. Finalmente, o índice de combinação (CI) de cada um dos quimio-agentes em combinação com o ODN foi estabelecido. Foi evidenciado que o HIF-1α ODN causa um efeito citotóxico em MDA-MB-231 de até 90% para 72h após o tratamento. Este efeito não é observado tanto nos controles do ensaio, como na cultura primária de células não tumorais (FIBRO), sendo este agente altamente seletivo para células tumorais, ativando mecanismos pró-apoptóticos. Por sua vez, o ODN de HIF-1α potencia a actividade tumorigénica da Cisplatina e do Taxol na linha celular do tumor. Portanto, o HIF-1α ODN demonstrou atividade antitumoral seletiva, diminuindo a proliferação celular e induzindo a apoptose; otimizar sinergicamente, a eficácia de drogas quimioterápicas de alto espectro, em tratamentos combinados.
References
Alborzinia, H., Can, S., Holenya, P.,Scholl, C., Lederer, E., Kitanovic, I., Wolf, S. (2011). Real-Time Monitoring of Cisplatin-Induced Cell Death. PLoS ONE, 6(5), e19714; 1-9. DOI: https://doi.org/10.1371/journal.pone.0019714
Callacondo-Riva, D., Quispe, M., Gamarra, L., Vaisberg, A. (2008). Actividad Citotóxica Del Extracto Etanólico De Gnaphalium Spicatum “Keto Keto” En Cultivos De Líneas Celulares Tumorales Humanas. Rev Peru Med Exp Salud Publica, 25(4), 380-85.
Cancer Today. [En línea] [Citado el: 23 de 05 de 2018.] http://gco.iarc.fr/today/fact-sheets-cancers?cancer=15&type=0&sex=2
Chou, Ting-Chao. (2006) Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. The American Society for Pharmacology and Experimental Therapeutics, 58(3), 621–681. DOI: https://doi.org/10.1124/pr.58.3.10
De Marzo A., Laughner E., Lim M., Hilton D., Zagzag D., Buechler P., Isaacs W., Semenza G., Simons J. (1999). Overexpression of Hypoxia-inducible Factor 1a in a Common Human Cancers and their Metastases. Cancer research, 59, 5830–5835.
Datta, K., Babbar, P., Srivastava, T., Sinha, S., Chattopadhyay, P. (2002). p53 dependent apoptosis in glioma cell lines in response to hydrogen peroxide induced oxidative stress. The International Journal of Biochemistry & Cell Biology, 34 (2), 148–157. DOI: https://doi.org/10.1016/S1357-2725(01)00106-6
Görlach, A. (2009). Regulation of HIF-1α at the Transcriptional Level. Current Pharmaceutical Design, 15(33). 3844-3852. DOI: https://doi.org/10.2174/138161209789649420
Guan, Y., Ramasamy-Reddy, K., Zhu, K., Li, Y., Lee, K., Weerasinghe, P., Prchal, J., Semenza, G., Jing, N. (2010). G-rich Oligonucleotides Inhibit HIF-1α and HIF-2α and Block Tumor Growth. The American Society of Gene & Cell Therapy, 18(1), 188–197. DOI: https://doi.org/10.1038/mt.2009.219
Harada, H., Inoue, M., Itasaka, S., Hirota, K., Morinibu, A., Shinomiya, K., Zeng, L., Ou, G., Zhu, Y., Yoshimura, M., McKenna, G., Muschen, R., Hiraoka, M. (2012). Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nature Communications, 3, 1-10. DOI: https://doi.org/10.1038/ncomms1786
Hernlund, E., Hjerpe, E., Avall-Lundqvist, E., Shoshan, M. (2009). Ovarian carcinoma cells with low levels of β-F1-ATPase are sensitive to combined platinum and 2-deoxy-Dglucose. Mol Cancer Ther., 8(7), 1916-1923. DOI: https://doi.org/10.1158/1535-7163.MCT-09-0179
Hu, Y., Jing, L., He, H. (2009). Recent Agents Targeting HIF-1a for Cancer Therapy. Journal of Cellular Biochemistry, 114(3), 498–509. DOI: https://doi.org/10.1002/jcb.24390
Jung, H., Lee, H., Cho, J., Chung, D., Yoon, S., Yang, Y., Lee, J., Choi, S., Park, J., Ye, S., Chung, M. (2005). Stat3 Is A Potential Modulator Of Hif-1-Mediated VEGF Expression In Human Renal Carcinoma Cells. Faseb Journal, 19(10), 1296-1298. DOI: https://doi.org/10.1096/fj.04-3099fje
Kimura, S., Kitadai, J., Tanaka, S., Kuwai, T., Hihara, J., Yoshida, K., Toge, T., Chayama, K. (2004). Expression of hypoxia-inducible factor (HIF)-1a is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. European Journal of Cancer, 40(12), 1904–1912. DOI: https://doi.org/10.1016/j.ejca.2004.04.035
Koukourakis, M., Giatromanolaki, A., Sivridis, E., Simopoulos, C., Turley, E., Talks, K., Gatter, D., Harris, A. (2002). Hypoxia-Inducible Factor (Hif-1α and Hif-2α), Angiogenesis, And Chemoradiotherapy Outcome Of Squamous Cell Head-And-Neck Cancer. Int. J. Radiation Oncology Biol Phys., 53(5), 1192–1202. DOI: https://doi.org/10.1016/S0360-3016(02)02848-1
Kung, A., Zabludoff, S., France, D., Freedman, S., Tanner, E., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., Memmert, K., Naegeli, H., Petersen, F., Eck, M., Bair, K., Wood, A., Livingston, D. (2004). Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell., 6(1), 33-43. DOI: https://doi.org/10.1016/j.ccr.2004.06.009
Leong, P., Andrews, G., Johnson, D., Dyer, K., Xi, S., Mai, J., Robbins, P., Gadiparthi, P., Burke, N., Watkins, S., Grandis, J. (2002). Targeted Inhibition of Stat3 With A Decoy Oligonucleotide Abrogates Head And Neck Cancer Cell Growth. PLoS ONE, 100 (7), 4138–4143. DOI: https://doi.org/10.1073/pnas.0534764100
Li, S., Shin, D., Chun, Y., Lee, M., Kim, M., Park, J. (2008). A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1A. Mol Cancer Ther., 7(12), 3929-3937. DOI: https://doi.org/10.1158/1535-7163.MCT-08-0074
Livak, K. and Schmittgen, T. (2001). Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2DCT. METHODS, 25(4), 402–408. DOI: https://doi.org/10.1006/meth.2001.1262
Luo, J., Solimini, L., Elledge, J. (2009). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell., 136(5), 823–837. DOI: https://doi.org/10.1016/j.cell.2009.02.024
Masoud G., Lin W. (2015). HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica, 5 (5), 378–389. DOI: https://doi.org/10.1016/j.apsb.2015.05.007
Ministerio de Salud y Protección Social, Colciencias, Instituto Nacional de Cancerología Empresa Social del Estado- Fedesalud. (2012). Guía de Atención Integral (GAI) para la Detección Temprana, Tratamiento Integral, Seguimiento y Rehabilitación del Cáncer de Mama. Colombia. GUÍA No 01.
Oon, E., Harris, A., Ashcroft, M. (2009). Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Reviews in Molecular Medicine, 11, 1-23. DOI: https://doi.org/10.1017/S1462399409001173
Pariente R , Pariente J, Rodríguez A, Espino J. (2016). Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: effects on oxidative stress and DNA fragmentation. Journal of Pineal Research, 60(1), 55-64. DOI: https://doi.org/10.1111/jpi.12288
Pariente R, Bejarano I, Espino J, Rodríguez A, Pariente J. (2017). Participation of MT3 melatonin receptors in the synergistic effect of melatonin on cytotoxic and apoptotic actions evoked by chemotherapeutics. Cancer Chemotherapy and Pharmacology, 80(5), 985-998. DOI: https://doi.org/10.1007/s00280-017-3441-3
Park E., Kong D., Fisher R., Cardellina J., Shoemaker R., Melillo G. (2006). Targeting the PAS-A Domain of HIF-1α for Development of Small Molecule Inhibitors of HIF-1. Cell Cycle, 5(16), 1847-1853. DOI: https://doi.org/10.4161/cc.5.16.3019
Rankin, E., & Giaccia, A. (2008).The role of hypoxia-inducible factors in tumorigenesis. Cell Death and Differentiation, 15 (4), 678–685. DOI: https://doi.org/10.1038/cdd.2008.21
Ruddon R. (2007). Cancer Biology. Oxford University Press 4TH ed. 17-55.
Siegel, R., Miller, K., Jemal, A. (2016). Cancer Statistics. Cancer J Clin., 68(1), 7–30p DOI: https://doi.org/10.3322/caac.21332
Sparano, J., Wang, M., Martino, S., Jones,V., Perez, E., Saphner, T., Wolff, A., Sledge, G., Wood, W., Davidson, N. (2008). Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. N Engl J Med. 358, 1663-1671. DOI: https://doi.org/10.1056/NEJMoa0707056
Sun, X., Vale, V., Jiang, X., Gupta, R., Krissansen, G. (2010). Antisense HIF-1a prevents acquired tumor resistance to angiostatin gene therapy. Cancer Gene Therapy, 17(8), 532–540. DOI: https://doi.org/10.1038/cgt.2010.7
Talks, K., Turley, H., Gatter, K., Maxwell, P., Pugh, C., Ratcliffe, P., Harris, A. (2000). The Expression and Distribution of the Hypoxia Inducible Factors HIF-1a and HIF-2a in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages. American Journal of Pathology, 157(2), 411-421. DOI: https://doi.org/10.1016/S0002-9440(10)64554-3
Wang G & Semenza G. (1993) Characterization of hypoxia inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem., 268(29), 21513–21518. DOI: https://doi.org/10.1016/S0021-9258(20)80571-7
Wigerup, C., Pahlman, S., Bexell, D. (2016). Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacology & Therapeutics, 164, 152–169. DOI: https://doi.org/10.1016/j.pharmthera.2016.04.009
Williams, K., Telfer, B., Xenaki, D., Sheridan, M., Desbaillets, I., Peters, H., Honess, D., Harris, A., Dachs, G., Kogel, A. Stratford, I. (2005). Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiotherapy and Oncology, 75(1), 89–98. DOI: https://doi.org/10.1016/j.radonc.2005.01.009
Yoshizumi, M., Imura, S., Sugimoto, K., Batmunkh, E., Kanemura, H., Morine, Y., Shimada, M. (2008). Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas, 36(3), 1-9. DOI: https://doi.org/10.1097/MPA.0b013e31815f2c2a
Ziegler, U, Groscurth, P. (2004). Morphological Features of Cell Death. News Physiol Sci., 19, 124-128. DOI: https://doi.org/10.1152/nips.01519.2004
Zhong, H., Mabjeesh, N., Willard, M., Simons, J. (2002). Nuclear expression of hypoxia-inducible factor 1a protein is heterogeneous in human malignant cells under normoxic conditions. Cancer Letters., 181(2), 233–238. DOI: https://doi.org/10.1016/S0304-3835(02)00053-8
How to Cite
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Download Citation
License
Copyright (c) 2020 Revista Colombiana de Biotecnología
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in the journal are welcome to code Creative Commons 4.0 Attribution, non-commercial, no derivatives. That is, that even as the Colombian Journal of Biotechnology of free access, users can download the information contained in it, but should give attribution or recognition of intellectual property, should use it as is, without derivation and should not be used with commercial purposes. Creative Commons This work is under a Creative Commons Attribution 4.0 License International. You are free: Share - copy and redistribute the material in any media or format Adapt - remix, transform and create from the material for any purpose, including commercial. The licensor can not revoke these freedoms while complying with the terms of the license. Under the following conditions: Attribution - You must properly acknowledge authorship, provide a link to the license and indicate whether changes have been made <. You can do this in any reasonable manner, but not in a way that suggests that support the licensor or receives for his use. No additional restrictions - You can not apply legal terms or technological measures that legally restrict realize what the license allows. notices: You do not have to comply with the license for those elements of the material in the public domain or where their use is permitted by the application of an exception or a limit. No guarantees are given. The license can not provide all the necessary permits for the intended use. For example, other rights such as advertising, privacy, or moral rights may limit the use of the material.